NCT04871854View on ClinicalTrials.gov

Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

July 26, 2022

Study Completion Date

August 26, 2022

Conditions
Breast Cancer
Interventions
DRUG

Tocilizumab

patients treated with Tocilizumab for Covid-19 infection

DRUG

traditional Covid -19 therapy

patients treated with traditional therapy for Covid-19 infection

Trial Locations (1)

11454

ALsafwa specialized hospital, Al Fayyum

All Listed Sponsors
lead

Beni-Suef University

OTHER